Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stifel dilution machine kicking in > 6.50
Should see tutes adding or buying PRQR shares all week. Pension plans, University endowment funds, mutual funds & hedge funds.
That's equal to half their market cap right now. Wait until this sinks in. I've been saying a confirmation of their RNA approach alone could be worth $40/sh here.
SEC filing 424B5 > closing of last month's shelf placement announcement possibly today.
PRQR
PT > $20. > Stifel analyst Dae Gon Ha initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Buy rating and announces Price Target of $20.
Milestone payments of up to $115 million plus royalties on future sales by Yarrow for an exclusive worldwide license and discovery collaboration on a non-ophthalmology target.
ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target
7:00 am ET May 4, 2021 (Globe Newswire) Print
-- Yarrow Biotechnology, Inc., a newly formed biotechnology company backed by RTW Investments, LP, will lead development of the program
-- ProQR Therapeutics is eligible to receive upfront and milestone payments of up to $115 million plus royalties on future sales by Yarrow for an exclusive worldwide license and discovery collaboration on a non-ophthalmology target
RTW Investments, LP ("RTW"), a global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors, and ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Yarrow Biotechnology, Inc. ("Yarrow") , a company newly created by RTW, has in-licensed exclusive rights to ProQR's antisense oligonucleotide technology (ASO) to develop and commercialize potential therapies for an undisclosed non-ophthalmic target. Yarrow is focused on developing ASO-based therapeutics for disorders with high unmet need.
Roderick Wong, MD, Managing Partner and Chief Investment Officer of RTW, said: "We believe RNA-based therapies hold great promise to treat genetically-defined diseases. We are excited to partner with ProQR to in-license the first target to be developed in Yarrow's pipeline."
Under the terms of the agreement, ProQR is eligible to receive up to $115 million of upfront and milestone payments, plus single digit percentage royalties on the net sales of any resulting products during the royalty term. ProQR will also have the right to receive an undisclosed percentage of equity in the form of shares of common stock of Yarrow. ProQR will be responsible for certain preclinical activities with reimbursement for the research costs by Yarrow, while Yarrow will be responsible for continuing development of the program and commercialization activities.
Gerard Platenburg, Chief Innovation Officer at ProQR, will join Yarrow's board of directors.
Peter Fong, PhD, Head of Company Creation at RTW, said: "Our partnership with ProQR fits perfectly into Yarrow's mission to develop first-in-class ASO-based therapies for genetically-defined diseases. We look forward to a long and productive partnership."
Daniel A. De Boer, Founder and CEO of ProQR, said: "As we focus ProQR on our core genetic eye disease strategy, we are pleased to partner with Yarrow to advance our technology in applications outside the eye, while generating value from this partnership and the broad applicability of our platform."
About RTW Investments, LP
RTW Investments, LP ("RTW") is a New York-based, global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors. As a leading partner of industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to support emerging medical therapies and the companies and academics developing them.
About Yarrow Biotechnology, Inc.
Yarrow Biotechnology, Inc. ("Yarrow") is a newly formed biotechnology company developing antisense oligonucleotide-based therapeutics for disorders with high unmet need. Yarrow has established a proprietary target discovery engine leveraging large-scale human genetics studies to uncover novel targets where there is a significant unmet need.
Yarrow is the latest new company created and backed by RTW Investments, LP.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Learn more about ProQR at www.proqr.com.
Forward Looking Statements for ProQR
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding the collaboration with RTW and Yarrow and the intended benefits thereof, including milestone and royalty payments from commercial product sales, if any, from the products covered by the collaboration and the issuance of equity in Yarrow to ProQR, as well as the potential of our technologies and product candidates. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted by the COVID-19 pandemic; the likelihood of our clinical programs being executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; and general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
For ProQR Therapeutics N.V.
Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
hans@lifesciadvisors.com
Media Contact:
Cherilyn Cecchini, MD
This will only keep going as more find it imo
ProQR Therapeutics started at buy with $20 stock price target at Stifel Nicolaus
Has data for 3rd program adRP later this year, pivotal LCA10 data 1H 22
Two drugs in phase II / III.
One of them (sepofarsen) already has papers published on the positive effect at 15 months. Confirmation of positive sepofarsen data will send this to $10+ near term imo.
My target by 2022 is $18/share.
Pushing 11k shares and adding
Nice.
I added at 6.13
Back in at $6.24 lego
I believe we see $10+ here very soon.
ProQR's sepofarsen shows promise in blindness study
Apr. 13, 2021 4:34 PM ETProQR Therapeutics N.V. (PRQR)By: Aakash Babu, SA News Editor
ProQR Therapeutics (NASDAQ:PRQR) highlights case study describing durable vision improvement after treatment with sepofarsen in a clinical trial for CEP290 mediated Leber congenital amaurosis 10 (LCA10), in the scientific journal Nature Medicine.
Sepofarsen (QR-110) is being evaluated in the pivotal Phase 2/3 Illuminate trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber congenital amaurosis 10 due to the c.2991+1655A>G mutation in the CEP290 gene.
Leber congenital amaurosis (LCA) is the most common cause of blindness due to genetic disease in children.
"Treatment with sepofarsen resulted in substantial, concordant and enduring improvement in more than a dozen different subjective and objective measurements of visual function as well as retinal structure," lead author Professor Artur V. Cideciyan said.
Published results highlight a patient who is homozygous for the c.2991+1655A>G mutation in CEP290 and was part of a larger cohort in the Phase 1/2 clinical trial. The patient was studied for 15 months after intravitreal treatment with sepofarsen.
Concordant measures of visual function and retinal structure including visual acuity, light sensitivity and visual fields, reached a substantial efficacy peak near three months after injection and remained better than baseline at 15 months.
Shares up more than 2% post market.
https://seekingalpha.com/news/3681528-proqr-highlights-publication-in-nature-medicine-for-sepofarsen-in-blindness-study
An End to This Rare Syndrome Could Be an Opportunity for Investors
https://www.fool.com/investing/2021/04/07/an-end-to-this-rare-syndrome-could-be-an-opportuni/?source=iedfolrf0000001
Exactly and always a given the SP will come down on an offering, the smart money buys on a selloff when the fundamental have not changed.
Seems pretty silly for retail to always dump "an offering" then. I guess retail gets upset that they spent $9 on shares that institutions get at $6.50 after the good news. Yes you own less proportional shares but the company is now cash rich through 2022+.
I can see this churning $6.50-8.00 until next material event or catalyst.
Large blocks are bought by the institutions wanting a higher percentage of the company shares rather than buying in the open market, driving up the share price.
How can an offering close without volume equal to the offering amount? Who bought the 13M shares if not from the open market the last 3 days.
Demand strong on the offering and now that it’s closed, it’ll be interesting to see where things go from here.
Good Luck!
This is a $20 stock in time, might be years not months but with the right news...
Your most welcome. (-;
Great article. Thanks for posting it.
A single injection reverses blindness in patient with rare genetic disorder
https://medicalxpress.com/news/2021-04-reverses-patient-rare-genetic-disorder.html
Sorry to hear that.
I was holding heavy at under $5, never sold a share (in the run, but sold some before it) but did sell otm (covered) calls at the end of the run for nice premium but bought a few back, profiting the spread but reacquiring the risk.
I think it’s an intriguing company with a compelling story behind it.
The capital raise was big (a qtr of the market cap) but this company doesn’t have a history of abusing its shareholders. They were already pretty well funded but now they’ll have a war chest. Supply is large.. the question is, what’s the demand like? We’ve got some momo and also headwinds.. hopefully the demand is sufficient to soak it up.
Good Luck!
ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares
Those covered calls sold at a nice premium are sure looking good in the rear view.
Covered some of my short. Pocketed the difference.
Good Luck!
* * $PRQR Video Chart 03-25-2021 * *
Link to Video - click here to watch the technical chart video
You never know. I couldn’t resist selling a few Oct calls strike 10 @330
But I’ve got a hefty position so should that occur, I won’t complain!
All the makings for $12 after hours IMO. Could open $15+ tomorrow before a major sell off.
Congrats!
Premium getting tasty on the long dated calls. Good way to lock profits and/or pad gains on the repricing climb (selling against your position).
All the best.
I'm up $34k and not a poster on here other than you my friend. Cheers.
Cantor raises target to $33 (from $22)
Citi upgraded to $44
JMP to $35
Current price - roughly $7
Good Luck!
Good idea. It’s bumping up against that 620 resistance right now. Hope it busts through!
Going to ride some free shares here when the dust settles on my swing trade. Neat company with a feel good problem to be apart of solving.
Cash runway into 2023.
presentation slides
I’m not an ophthalmologist (calling Dr. Rand Paul) but listening in to the call sounds awfully positive. Safe and well tolerated with no SAE’s. Meeting all endpoints. It was with a single injection too with the data showing a second dosing at around 6 months might give added benefit.
This next P2/3 trial (x2 parallel studies) is going to be really interesting. End of 2021. I believe he said the trials would be 18 months long with a possible interim readout at 12 months.
Edit - compelling presentation. I may stick around longer than I anticipated. Good problems.
I agree. Conference call at 830est
Hoping for a convincing break through 6.20 to a short term $7 target (Note that I change my mind as I see patterns develop). Traders perspective. I sold some of my $5 position at 6.05 to lower my risk going into these results.
Edit - This is a very intriguing company and although I’m primarily trading, I’m considering keeping a core position longer term. Especially if we have a big move north.
Good Luck!
Nice news, price target for you?
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
158
|
Created
|
09/18/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |